Cited by 155Cancer-related Molecular PathwaysCancer-related molecular mechanisms researchTelomeres, Telomerase, and Senescence

Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway

Open access
Xie, Haibiao, Ma, Kaifang, Zhang, Kenan, Zhou, Jingcheng, Li, Lei, Yang, Wuping, Gong, Yanqing, Cai, Lin +1 more·2021·Cell Death & Disease

Abstract

TP53 is a classic tumor suppressor, but its role in kidney cancer remains unclear. In our study, we tried to explain the role of p53 in kidney cancer through the p53-related enhancer RNA pathway. Functional experiments were used to explore whether P53-bound enhancer regions 2 (p53BER2) has a role in the cell cycle and senescence response of TP53-wild type (WT) renal cancer cells in vitro or vivo. RNA-sequencing was used to identify the potential target of p53BER2. The results showed that the expression level of P53BER2 was downregulated in renal cancer tissues and cell lines, further dual-luciferase experiments and APR-256-reactivated experiments showed p53BER2 expresses in a p53-dependent way. Moreover, knockdown p53BER2 could reverse nutlin-3-induced cytotoxic effect in TP53-WT cell lines. Further exploration showed the downregulation of p53BER2 could reverse nutlin-3-induced G1-arrest and senescence in TP53-WT cell lines. What is more, the knockdown of p53BER2 showed resistance to nutlin-3 treatment in vivo. Additionally, we found BRCA2 could be regulated by p53BER2 in vitro and vivo; further experiment showed p53BER2 could induce cell-cycle arrest and DNA repair by mediating BRCA2. In summary, the p53-associated enhancer RNA-p53BER2 mediates the cell cycle and senescence of p53 in TP53-WT renal cancer cells.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-020-03229-8

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Methotrexate is a chemotherapeutic agent that inhibits DNA synthesis by targeting dihydrofolate reductase.

    “Methotrexate (MTX) is a chemotherapeutic agent that inhibits DNA synthesis by targeting dihydrofolate reductase47, an enzyme needed for biosynthesis of nucleic acid precursors and some amino acids.”

    From A statistical framework for high-content phenotypic profiling using cellular feature distributions (2022) · cites this paper as [47]

    The Results discuss p53BER2, BRCA2, and DNA repair, while the Materials and methods name nutlin-3 and PRIMA-1-met as drugs used in the experiments. Searches for methotrexate, MTX, and dihydrofolate reductase found no passage addressing the claimed mechanism. Our copy therefore cannot verify this attribution. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 50 · Cited by 155

Authors
Xie, H., Ma, K., Zhang, K., Zhou, J., Li, L., Yang, W., Gong, Y., Cai, L., & Gong, K.
Affiliations
Peking University (CN)
Corresponding author
  • Gong, Yanqing
  • Cai, Lin
  • Gong, Kan
Venue
Cell Death & Disease
Published
2021-01-05
Volume
12
Issue
1
Pages
1-1
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3111404439
Cited by
155
References
50
Citations by year
2026: 5 · 2025: 38 · 2024: 32 · 2023: 30 · 2022: 32 · 2021: 18
FWCI
10.20
Type
journal article
Language
en
Open access
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
National Natural Science Foundation of China (81872081)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
Keywords
p53, renal carcinoma, enhancer RNA, cell cycle arrest, cellular senescence, G1 cell cycle arrest, BRCA2, DNA repair, p53-dependent pathway
MeSH terms
Animals, Carcinoma, Renal Cell, Humans, Kidney Neoplasms, Male, Mice, Nude, Middle Aged, Transfection, Biomarkers, Tumor, Tumor Suppressor Protein p53, Cell Proliferation, Mice, Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review